Actithera
Next-generation radioligand therapies designed for prolonged tumor retention
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Actithera is a radiopharmaceutical biotechnology company developing radioligand therapies that link radioactive isotopes to designed molecules for targeted cancer treatment. The company aims for prolonged tumor retention while limiting exposure to healthy tissue, with programs advancing toward clinical development. Actithera has offices in Cambridge, Massachusetts, and Norway.
- Website
- actithera.com
- Added via
- web
- Ownership
- unclaimed